Carolyn J. LaVita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carolyn J. LaVita has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Maurizio Cereda
Drs. Gaulton, Ribeiro De Santis Santiago, Cereda, and Berra, Mr. Morais, and Dr. Alcala are affiliated with the Department of Anesthesiology, Massachusetts General Brigham, Boston, Massachusetts
2 shared publications- Angela R. Shih
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA
1 shared publication - Bijan Safaee Fakhr
Mass General Brigham, Harvard Medical School, Boston, Massachusetts
1 shared publication - Binglan Yu
Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA
1 shared publication Caio César Araújo Morais
Drs. Gaulton, Ribeiro De Santis Santiago, Cereda, and Berra, Mr. Morais, and Dr. Alcala are affiliated with the Department of Anesthesiology, Massachusetts General Brigham, Boston, Massachusetts
1 shared publication- Cristina Mietto
Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
1 shared publication
Latest Publications
- 23 September 2026
- Published by SAGE Publications in Respiratory Care
The Response of Dorsal Lung Compliance to Prone Positioning Differs by Body Mass Index in ARDS
Background: Excess adipose tissue compresses dorsal lung regions that PEEP may not fully reverse in the supine position. Prone positioning, in combination with PEEP, can unload the lung, but whether regional responses differ by obesity is unknown. Methods: We measured regional lung compliance using electrical impedance tomography in 14 mechanically ventilated subjects with COVID-19 ARDS (6 with BMI ≥35 kg/m 2 and 8 with BMI 2 ). Measurements were taken during decremental PEEP titration in supine and prone positions, following recruitment maneuvers. Regional compliance was derived from pixel-level impedance change within each region of interest, divided by driving pressure and predicted body weight. Bayesian multilevel gamma regression models with patient-level random effects estimated the 3-way interaction between position, BMI group, and lung region on regional compliance, adjusted for age. Results: The overall cohort had a median P aO 2 /F IO 2 of 108 mm Hg and median respiratory system compliance of 29 mL/cm H 2 O in the supine position. At the PEEP that produced the highest total respiratory system compliance in each position, the increase in dorsal regional compliance with prone positioning was greater in subjects with BMI ≥35 kg/m 2 compared with subjects with BMI 2 (difference-in-differences: 0.16 mL/cm H 2 O/kg, 95% credible interval: 0.01 to 0.37; posterior probability: 98.0%). Regional compliance in ventral and central lung regions did not credibly differ between BMI groups. The direction and magnitude of the change in dorsal lung compliance between BMI groups were consistent across PEEP levels. Conclusions: Prone positioning was associated with a greater increase in dorsal lung compliance in subjects with BMI ≥35 kg/m 2 compared with subjects with BMI 2 . Our findings suggest that the response of regional compliance to prone positioning in ARDS differs by body mass index, identifying obesity as a population in whom positional unloading may be more effective.
- 23 September 2026
- Published by SAGE Publications in Respiratory Care
The Response of Dorsal Lung Compliance to Prone Positioning Differs by Body Mass Index in ARDS
Background: Excess adipose tissue compresses dorsal lung regions that PEEP may not fully reverse in the supine position. Prone positioning, in combination with PEEP, can unload the lung, but whether regional responses differ by obesity is unknown. Methods: We measured regional lung compliance using electrical impedance tomography in 14 mechanically ventilated subjects with COVID-19 ARDS (6 with BMI ≥35 kg/m 2 and 8 with BMI 2 ). Measurements were taken during decremental PEEP titration in supine and prone positions, following recruitment maneuvers. Regional compliance was derived from pixel-level impedance change within each region of interest, divided by driving pressure and predicted body weight. Bayesian multilevel gamma regression models with patient-level random effects estimated the 3-way interaction between position, BMI group, and lung region on regional compliance, adjusted for age. Results: The overall cohort had a median P aO 2 /F IO 2 of 108 mm Hg and median respiratory system compliance of 29 mL/cm H 2 O in the supine position. At the PEEP that produced the highest total respiratory system compliance in each position, the increase in dorsal regional compliance with prone positioning was greater in subjects with BMI ≥35 kg/m 2 compared with subjects with BMI 2 (difference-in-differences: 0.16 mL/cm H 2 O/kg, 95% credible interval: 0.01 to 0.37; posterior probability: 98.0%). Regional compliance in ventral and central lung regions did not credibly differ between BMI groups. The direction and magnitude of the change in dorsal lung compliance between BMI groups were consistent across PEEP levels. Conclusions: Prone positioning was associated with a greater increase in dorsal lung compliance in subjects with BMI ≥35 kg/m 2 compared with subjects with BMI 2 . Our findings suggest that the response of regional compliance to prone positioning in ARDS differs by body mass index, identifying obesity as a population in whom positional unloading may be more effective.
- 21 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (833) , eady2646
Inhaled nitric oxide at 300 ppm treats multidrug-resistant Pseudomonas pneumonia in swine and is safe in humans
Antibiotic resistance in respiratory infections is an escalating global concern that requires innovative antimicrobial approaches. Pseudomonas aeruginosa is a common multidrug-resistant pathogen and a major cause of hospital-acquired pneumonia. Accumulating evidence suggests that, at high doses, inhaled nitric oxide (iNO) acts as a potent antimicrobial agent. This study evaluated the efficacy and safety of iNO at 300 parts per million (iNO 300 ) as a treatment for P. aeruginosa infection. In vitro, P. aeruginosa exhibited a dose-dependent reduction when exposed to an NO donor. In a mechanically ventilated swine model of P. aeruginosa pneumonia, intermittent iNO 300 therapy resulted in a two-log reduction in bacterial burden, improved oxygenation and lung compliance, and reduced histopathological lung injury. A phase 1 clinical trial in 10 healthy individuals confirmed the safety of intermittent iNO 300 therapy with no adverse events. In two critically ill patients with multidrug-resistant bacteria, who were in the intensive care unit, iNO 300 was well tolerated, demonstrating clinical feasibility. Long-term follow-up of patients exposed to high-dose iNO for more than 6 years revealed no adverse outcomes. Our findings establish iNO 300 as a promising antimicrobial agent against P. aeruginosa pneumonia, warranting further clinical evaluation.
- 21 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (833) , eady2646
Inhaled nitric oxide at 300 ppm treats multidrug-resistant Pseudomonas pneumonia in swine and is safe in humans
Antibiotic resistance in respiratory infections is an escalating global concern that requires innovative antimicrobial approaches. Pseudomonas aeruginosa is a common multidrug-resistant pathogen and a major cause of hospital-acquired pneumonia. Accumulating evidence suggests that, at high doses, inhaled nitric oxide (iNO) acts as a potent antimicrobial agent. This study evaluated the efficacy and safety of iNO at 300 parts per million (iNO 300 ) as a treatment for P. aeruginosa infection. In vitro, P. aeruginosa exhibited a dose-dependent reduction when exposed to an NO donor. In a mechanically ventilated swine model of P. aeruginosa pneumonia, intermittent iNO 300 therapy resulted in a two-log reduction in bacterial burden, improved oxygenation and lung compliance, and reduced histopathological lung injury. A phase 1 clinical trial in 10 healthy individuals confirmed the safety of intermittent iNO 300 therapy with no adverse events. In two critically ill patients with multidrug-resistant bacteria, who were in the intensive care unit, iNO 300 was well tolerated, demonstrating clinical feasibility. Long-term follow-up of patients exposed to high-dose iNO for more than 6 years revealed no adverse outcomes. Our findings establish iNO 300 as a promising antimicrobial agent against P. aeruginosa pneumonia, warranting further clinical evaluation.